trastuzumab + cisplatin + capecitabine

A combination regimen of **trastuzumab**, **cisplatin**, and **capecitabine** is used primarily for the treatment of **HER2-positive advanced gastric or gastroesophageal junction cancer**. - **Trastuzumab** is a recombinant humanized monoclonal IgG1 antibody targeting the extracellular domain of the HER2 (human epidermal growth factor receptor 2), inhibiting receptor dimerization, preventing activation of HER2-mediated intracellular signaling, inducing antibody-dependent cellular cytotoxicity (ADCC), and inhibiting downstream MAPK and PI3K/AKT pathways, ultimately suppressing tumor cell proliferation and survival[2][6]. - **Cisplatin** is a platinum-based chemotherapeutic agent that crosslinks DNA, leading to apoptosis of rapidly dividing cells. - **Capecitabine** is an orally administered pro-drug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo; it inhibits thymidylate synthase, impairing DNA synthesis and triggering cell death, especially in rapidly dividing tumor cells[3]. This triple combination has been investigated and is used in clinical practice primarily as a first-line treatment option for patients with HER2-positive disease[5]. Capecitabine and cisplatin serve as cytotoxic backbone chemotherapy, while trastuzumab provides targeted anti-HER2 activity.

Brand names

SamfenetHerceptinXeloda

Other names

trastuzumab plus capecitabine and cisplatinXP-trastuzumabXP regimen plus trastuzumab